NEEL Gel skips the usual cosmetic-industry playbook for a biotech approach built around a single peptide.
Most skincare lines start with a formulator and a marketing brief. NEEL Gel started with longevity researchers at Yuvan Research Inc. and a peptide that’s been drawing attention in genomics circles for reasons that have nothing to do with wrinkles. The company markets the gel less on cosmetic promises and more on a claim that’s unusual for the beauty aisle: that it targets biological aging at the gene level. It’s patented technology, and its most notable daily user is a name genomics researchers would recognize — Stanford Genetics professor Dr. Michael Snyder.
The Peptide Behind It
The formula centers on GHK-Cu, a naturally occurring peptide the body produces less of with age. Interest in it accelerated after researchers used gene-expression data from the Broad Institute — a joint MIT and Harvard research center — to show that GHK-Cu could shift the activity of roughly a third of the genes analyzed toward patterns associated with younger tissue.
Turning that data point into a usable product took Yuvan Research three years. GHK-Cu is unstable in the presence of oxygen, which is a real problem for a skincare product that has to survive a shelf, a bathroom cabinet, and repeated air exposure every time it’s opened. The company’s answer was to move away from standard jars and tubes toward an applicator engineered to limit air contact and preserve the peptide’s potency.
What the Clinical Trial Found
Rather than relying on lab data alone, Yuvan Research put the gel through an Institutional Review Board–approved clinical trial, run by a professor of dermatology at Royal Victoria Hospital, McGill University. Twenty-one middle-aged women used the gel daily for three months; before-and-after ultrasound imaging measured the change in their skin. On average, collagen fiber density increased by 28 percent — a meaningful figure given that collagen makes up 60 to 70 percent of the skin’s structure.
The Snyder Connection
The product’s profile got a boost from a name well known in genomics: Dr. Michael Snyder, director of Stanford’s Center for Genomics and Personalized Medicine. In a video interview produced by Yuvan Research, Snyder says he’s used NEEL Gel daily for more than two years and describes it as one of the only skincare products in his personal routine, alongside a moisturizer. It’s worth being clear about the source here — the interview is company-produced, not independent reporting on Snyder’s routine — but Snyder is a real, prominent figure in the genomics field, and his willingness to put his name behind the product is notable regardless of who filmed the conversation.
Beyond Skincare
Yuvan Research is now exploring GHK-Cu outside topical use. An early trial, led by a hospital gastroenterology department, is testing an oral form of the peptide alongside another compound for inflammatory bowel disease. So far, four patients have reportedly seen their colitis go into remission within two months of treatment. That’s a very small, uncontrolled sample with no published data yet — worth watching, but nowhere near evidence that oral GHK-Cu treats IBD, and not something anyone should act on outside of a monitored clinical trial.
For now, Yuvan Research’s stated focus remains where it started: developing science-backed approaches to the biological mechanisms behind skin aging.
